// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Examining the relationship between the clinical benefit of oncology drug indications and the time from pan-Canadian Oncology Drug Review (pCODR) recommendation to public reimbursement.

Sasha Thomson - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

First-line CyborD treatment for graft ineligible multiple myeloma patients: Real-life efficacy and tolerability.

Dominic Duquette - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Risk of chronic opioid use after radiation for head and neck cancer: A systematic review and meta-analysis.

Sondos Zayed - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Epimorph

Quality assessment of online hepatocellular carcinoma patient education materials.

Jim (Zhang Hao) Li - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Depression in cancer: An evaluation of patient education resources.

Jim (Zhang Hao) Li - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Risk of cancer-specific death for patients diagnosed with neuroendocrine tumors: A population-based analysis.

Julie Hallet - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Macrocytosis as a predictor of response to capecitabine in solid cancers: A meta-analysis.

Fahad Almugbel - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Capecitabine

Dementia risk among post-menopausal women treated with endocrine therapy for early-stage breast cancer in Ontario, Canada.

Phillip S. Blanchette - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Tamoxifen

The Quebec Cannabis Registry: a pharmacovigilance and effectiveness study on the use of medical cannabis in cancer patients.

Antonio Vigano - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Methodology, results, and publication of oncology clinical trials: Insights from all the world’s randomized controlled trials (RCTs) 2014-2017.

Shubham Sharma - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

The impact of primary pancreatic tumor location on clinical outcomes in advanced disease: Results from the chord consortium.

Abdulaziz AlJassim AlShareef - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Exomes and transcriptomes to reveal actionable findings in patients with negative-targeted panel sequencing.

Eric Y. Zhao - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Is there a role for hypofractionated thoracic radiotherapy in limited-stage small cell lung cancer? a propensity score matched analysis.

Sondos Zayed - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

An analysis of growth in the genetic counseling profession 2009 to 2019.

Gillian Hooker - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Impact of oligometastatic disease on survival in ER positive breast cancer: A population-based analysis.

Nathalie LeVasseur - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Does CNS metastases reduce systemic therapy lines for NSCLC patients with EGFR mutation?

Danilo Giffoni - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Tagrisso

Age-related lymphoma patient experience: Results from the Lymphoma Coalition 2018 Global Patient Survey.

Raul Cordoba - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Usage and factors associated with adjuvant bisphosphonate therapy among postmenopausal women diagnosed with early-stage breast cancer.

Veera Durga Sravanthi Panuganty - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Clinicopathological features and treatment outcomes of young patients with gastric and esophageal cancers.

Lauren Amanda Beck - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients.

Afshin Dowlati - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Carboplatin

Copyright © 2026. QuantiNova All rights reserved